1. Introduction {#sec1}
===============

Under physiological conditions, the vascular endothelium produces many substances that contribute importantly to hemostasis, fibrinolysis, and regulation of vessel tone and permeability \[[@B1]\]. One such substance is glycoprotein von Willebrand factor (vWf), which is almost exclusively produced by the endothelium, and thus is a marker of endothelial activation or dysfunction \[[@B2]--[@B4]\]. vWf mediates platelet adhesion to the vascular wall, platelet aggregation and serves as a plasma carrier for factor VIII, stabilizing it in the circulation \[[@B5]\]. Since almost all acute coronary syndromes (ACSs) result from thrombus formation in preexisting atherosclerosis \[[@B1]\], and given the key role of vWf in arterial thrombus formation, this biomarker attracted considerable interest as a predictor of cardiovascular disease (CVD) \[[@B1], [@B5]\]. Previously published studies suggest that there is a weak association between vWf plasma levels and risk of coronary heart disease (CHD) in general population, but its predictive value significantly rises in patients with preexisting vascular disease, diabetics, and the elderly \[[@B6]--[@B9]\]. It was noticed that vWf rises during the course of ACSs \[[@B4], [@B10], [@B11]\], and it is thought that vWf is not only a marker, but also a mediator in the pathogenesis of myocardial infarction (MI) \[[@B1]\]. Although a number of studies pointed out the prognostic value of vWf \[[@B12]--[@B14]\], there is still a long way to go before plasma vWf levels can be used as a predictor of cardiovascular disease in clinical practice \[[@B5]\].

von Willebrand factor can be produced and released by endothelial cells by a variety of stimuli in vitro and in vivo \[[@B5], [@B15], [@B16]\]. A number of substances regulate endothelial release of vWf. Among other secretion agonists and antagonists, like numerous mediators of inflammation and/or thrombosis, reactive oxygen species (ROS) play an important role. For example, superoxide anion radical (O~2~ ^−^) is considered to be activator of endothelial exocytosis \[[@B17]\], while hydrogen peroxide (H~2~O~2~) has been shown to inhibit thrombin-induced vWf secretion in a dose-dependent manner \[[@B18]\]. On the other hand, H~2~O~2~ induced a weak secretory response \[[@B19]\]. Thus, the effects of H~2~O~2~ are still to be investigated. Nitric oxide (NO) is another reactive substance that exhibits inhibitory effects on vWf secretion, but its effects are also yet to be elucidated, since the majority of research was performed on cultured endothelial cells, which may not be the ideal tool to study the effects of nitric oxide (NO) \[[@B5]\].

Emerging data suggest that acute presentations of coronary artery disease may involve a complex interplay between the vessel wall, inflammatory cells, and the coagulation cascade. Considering the role of vWf in hemostasis and the role of oxidative stress in the development of endothelial dysfunction and atherosclerotic disease \[[@B20]--[@B23]\], the aim of our study was to investigate the relationship between von Willebrand factor and parameters of oxidative stress on the one side and different types of acute coronary syndromes on the other.

2. Results {#sec2}
==========

Demographic data of investigated groups are shown in [Table 1](#tab1){ref-type="table"}.

The results of comparison of investigated biochemical parameters in patients and controls are shown in Figures [1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, [7](#fig7){ref-type="fig"}, [8](#fig8){ref-type="fig"}, and [9](#fig9){ref-type="fig"}.

Results of uni- and multivariant logistic regression related to the effects of ACSs existence to changes in examined biochemical parameters are shown in [Table 2](#tab2){ref-type="table"}. Results of univariant logistic regression marked vWfAg, vWfAct, NO~2~ ^−^, H~2~O~2~, TBARS, SOD, and CAT as significant. Univariant logistic regression shows the existence of differences in investigated parameters in existance of all other factors, while multivariant logistic regression marks parameters that are changed under independent effect of ACSs existance. Multivariant logistic regression did not mark any parameter as significant.

Frequency of elevated levels of vWfAct (above 163, range of referent values 48.8%--163%) and vWfAg (above 158, range of reerent values: 61.3%--158%) in ACSs patients and controls are shown in [Table 3](#tab3){ref-type="table"}. *χ* ^2^ test showed that groups of ACSs patients and controls differed significantly in frequency of elevated levels of both vWfAct and vWfAg (*P* = 0.000 for both).

Based on the data presented in [Table 3](#tab3){ref-type="table"}, sensitivity and specificity of the test (measuring vWfAct and vWfAg levels) were calculated. Sensitivity, as an indicator of the test\'s ability to reveal patients with disease (ACSs) was 53.91% for vWfAct and 86.0% for vWfAg, while specificity, as an indicator of test\'s ability to revel healthy subjects, was 97.5% for vWfAct and 100.00% for vWfAg. Receiver operating characteristic (ROC) curve ([Figure 9](#fig9){ref-type="fig"}) shows discriminative ability of the test.

[Table 4](#tab4){ref-type="table"} shows levels of investigated parameters in groups of patients with different type of ACSs. Results of uni- and multivariant logistic regression related to the effects of different type of ACSs existence to changes in examined biochemical parameters are shown in [Table 5](#tab5){ref-type="table"}. Univariant logistic regression marked vWfAg, vWfAct, NO~2~ ^−^, H~2~O~2~, TBARS, and SOD as significant, while multivariant analysis showed that only vWfAg and TBARS were under independent effect of ACSs type.

[Table 6](#tab6){ref-type="table"} shows data about investigated biochemical parameters in ACSs patients who survived and who deceased. There was no significant difference in any investigated biochemical parameter between these groups.

Results of univariant logistic regression regarding effects of levels of biochemical parameters on outcome (survival or lethal event) of ACSs patients showed that no biochemical parameter was revealed as significant, so multivariant logistic regression was not performed ([Table 7](#tab7){ref-type="table"}).

3. Discussion {#sec3}
=============

Biomarkers play a pivotal role in the diagnosis and treatment of patients with cardiovascular disease \[[@B24]\]. Advances in our understanding of the pathophysiology of ACSs have led to the marked increase in development of biomarkers for diagnosis, risk stratification, therapeutic decision making, and assessment of clinical outcomes \[[@B25]--[@B27]\]. A lot of new markers measuring various components of the acute atherothrombotic event have been described, and novel biomarkers of endothelial activation, inflammation, coagulation, and platelet activation are intensively investigated \[[@B28]--[@B31]\]. Among other perspective prognostic biomarkers that have not been incorporated into routine clinical use yet, von Willebrand factor rises considerable attention.

Many different vWf-dependent laboratory assays have been developed to correctly diagnose and classify von Willebrand disease \[[@B32]\]. However, when investigating vWf as a risk factor for cardiovascular disease, assays for plasma vWf antigen and plasma vWf activity are used in most cases \[[@B1]\]. ACSs patients in our study had significantly elevated levels of both vWfAct and vWfAg compared with healthy control subjects. Levels of vWfAct did not differ significantly among patients with different type of ACSs; vWfAct was elevated only in STEMI (ST elevation MI) and NSTEMI (non-ST elevation MI) ACSs patients, while patients with unstable angina had vWfAct levels similar to control subjects. Regarding vWfAg, there were significant differences in its level among patients with different types of ACSs as well as between controls and STEMI and NSTEMI patients. Only vWfAg levels of patients with UA did not differ from controls. The results of our study are in consent with previously reported data. Spiel et al. \[[@B1]\] and Paulinska et al. \[[@B16]\] reported that the published vWf data \[[@B10], [@B11], [@B33]--[@B37]\] shows that patients with acute myocardial infarction (AMI) have markedly increased vWf values compared with unstable angina (UA) and coronary artery disease (CAD) patients as well as compared with healthy control subjects. That vWf is biochemical parameter that distinguishes well between the healthy and people with ACSs our study proved not only by assessing differences in its levels between ACSs patients and controls, but also by comparing the frequency of the existance of elevated vWf levels in these two groups as well as by counting its specificity and sensitivity. Sensitivity of vWfAg, as an indicator of its ability to reveal patients with disease, was 86%, while its specificity, as an indicator of its ability to reveal healthy subjects, was 100%. Sensitivity of vWfAct was significantly lower, but its specificity was also very high (97.5%). As it can also be seen from [Figure 9](#fig9){ref-type="fig"} that shows ROC curves for vWfAct and vWfAg, the strength of vWfAg as an indicator of ACSs existance is very high. Results of logistic regression also highlighted this parameter as significant---univariant logistic regression showed that type of ACSs affects both vWfAct and vWfAg levels, but multivariant regression marked only vWfAg as the one whose change is under independent effect of ACSs type not due to existance of other cofactors.

The results of previous studies regarding prognostic value of vWf for cardiovascular events are equivocal. Many studies found increased relative risk in subjects with the highest levels of vWf \[[@B6], [@B38], [@B39]\], but in the majority of studies, the association between vWf and CHD risk disappeared after adjustment for conventional risk factors \[[@B8], [@B9]\]. However, in contrast to results of studies performed in the general population, in patients with preexisting vascular disease, vWf revealed as significantly predictive parameter for adverse cardiac events, including death \[[@B13], [@B14], [@B40]--[@B42]\]. Our study was not prospective, but since 4 patients died few days after admission, we compared their admission levels of investigated biochemical parameters with levels of patients that survived. No statistical difference was found, neither in vWfAct and vWfAg levels, nor in levels of redox parameters.

The second part of our investigation related to the assessment of subjects\' redox state. Oxidative stress has been suggested to play an important role in the development of more than two hundred acute and chronic human diseases as well as in aging \[[@B21]--[@B23], [@B43]--[@B46]\]. The results of our study showed that ACSs patients had significantly less efficient antioxidative defence system compared with controls (significantly lower levels of SOD and CAT activity) which resulted in significantly increased levels of lipid peroxidation. Furthermore, ACSs patients had significantly lower levels of nitric oxide (nitrites), which is an indicator of endothelial dysfunction. Suprisingly, H~2~O~2~ levels of ACSs patients were significantly lower than controls\'. The fact that ACSs patients had lower NO and H~2~O~2~ levels may be brought into connection with vWf levels, since reactive oxygen species and NO are involved in the regulation of vWf release. It was previously suggested that the blockade of nitric oxide enhances the stimulated release of vWf in humans \[[@B47], [@B48]\], that is, NO exerts inhibitory effects on vWf release \[[@B5]\]. So, is thought for H~2~O~2~ \[[@B5]\]. ACSs patients were deficient in NO and H~2~O~2~ compared with controls, so NO and H~2~O~2~ inhibition of vWf release was probably lower. When comparing oxidative status of patients with different ACSs types, only SOD differed between STEMI and UA patients (UA patients had lower SOD activity). On the other hand, whenever the difference among 4 groups (3 ACSs groups and control group; [Table 4](#tab4){ref-type="table"}) was found, it related to differences between every group of ACSs patients and controls. These results suggest that ACSs patients are under higher oxidative stress compared with control subjects, no matter which type of ACSs they have. However, although ACSs patients differed from controls in a few oxidative stress parameters, only TBARS was found to be under the independent effect of ACSs type.

The results of our study point out to von Willebrand factor antigen as strong indicator of existance of any kind of ACSs. This supports the implementation of vWf in clinical routine and into therapeutic targets. Results related to the investigation of oxidative stress in ACSs patients suggest that antioxidant supplementation is needed to improve the antioxidant defence, since enzymatic antioxidant defense is compromised and lipid peroxidation consequently increased in those patients.

4. Patients and Methods {#sec4}
=======================

4.1. Subjects {#sec4.1}
-------------

The research was carried out within a group of 115 patients who were consecutively admitted to the Intensive Care Unit of University Hospital Center "Kragujevac", Serbia. All patients met the criteria for ACSs diagnosis (the presence of two out of these three criteria is enough to diagnose ACSs): (1) chest pain, (2) electrocardiographic changes (ST elevation or depression ≥1 mm, or T wave inversion), and (3) serum cardiac markers changes (creatine kinase (CK), creatine kinase MB (CK-MB), and troponin T (TnT)) \[[@B49]\]. The diagnosis of STEMI was defined as the concurrence of prolonged chest pain or discomfort with persistent ST-segment elevation of greater than 1 mm in 2 or more contiguous leads or with presumed new left bundle-branch block with cardiac enzymes (total creatine kinase and creatine kinase MB fraction) above twice the upper normal limit \[[@B50]\]. The diagnosis of NSTEMI included the presence of typical angina at rest associated with acute and transient ST-segment or T-wave changes with cardiac enzymes above twice the upper normal limit, raised troponin I levels to at least "high risk" values (\>0.6 ng/mL), or both \[[@B50]\]. Patients with clinical or electrocardiographic (ECG) features of non-STEMI but with normal cardiac enzymes plus normal troponin levels were classified as UA \[[@B50]\].

The study was approved by Ethical committee of University Hospital Center "Kragujevac", Serbia.

4.2. Protocol {#sec4.2}
-------------

After admission to hospital patients were taken a blood sample from which von Willebrand factor activity (vWfAct), von Willebrand antigen (vWfAg), levels of nitric oxide (NO), superoxide anion radical (O~2~ ^−^), hydrogen peroxide (H~2~O~2~), index of lipid peroxidation (TBARS), superoxide dismutase activity (SOD), and catalase activity (CAT) were determined.

4.3. Biochemical Assays {#sec4.3}
-----------------------

Blood samples were taken from the antecubital veins into Vacutainer test tube containing sodium citrate anticoagulant. Blood was centrifuged to separate plasma and red blood cells (RBCs).

4.4. von Willebrand Factor Activity and von Willebrand Factor Antigen Determination {#sec4.4}
-----------------------------------------------------------------------------------

Determination of vWfAct and vWfAg was performed using commercial assay kit (HemosIL 0020004700 and 0020002300) on ACL Elite Pro apparatus manufactured by Instrumentation Laboratory, Bedford, Mass, USA. vWfAct and vWfAg results are reported in % of normality.

4.5. Nitric Oxide Determination {#sec4.5}
-------------------------------

Nitric oxide (NO) decomposes rapidly to form stable metabolite nitrite/nitrate products. Nitrite (NO~2~ ^−^) was determined as an index of nitric oxide production with Griess reagent \[[@B51]\]. 0.1 mL 3N PCA (Perchloride acid), 0.4 mL 20 mM EDTA (ethylenediaminetetraacetic acid), and 0.2 mL plasma were put on ice for 15 min then centrifuged 15 min at 6000 rpm. After pouring off the supernatant, 220 *μ*L K~2~CO~3~ was added. Nitrites were measured at 550 nm. Distilled water was used as a blank probe.

4.6. Superoxide Anion Radical Determination {#sec4.6}
-------------------------------------------

The level of superoxide anion radical (O~2~ ^−^) was measured using NBT (nitro blue tetrazolium) reaction in TRIS-buffer combined with plasma samples and read at 530 nm \[[@B52]\].

4.7. Hydrogen Peroxide Determination {#sec4.7}
------------------------------------

The protocol for measurement of hydrogen peroxide (H~2~O~2~) is based on oxidation of phenol red in the presence of horseradish peroxidase \[[@B53]\]. Two hundred *μ*L sample with 800 *μ*L PRS (phenol red solution) and 10 *μ*L POD (horse radish peroxidase) were combined (1 : 20). The level of H~2~O~2~ was measured at 610 nm.

4.8. Index of Lipid Peroxidation (Thiobarbituric Acid Reactive Substances, TBARS) {#sec4.8}
---------------------------------------------------------------------------------

The degree of lipid peroxidation in plasma was estimated by measuring of thiobarbituric acid reactive substances (TBARS) using 1% TBA (Thiobarbituric Acid) in 0.05 NaOH, incubated with plasma at 100°C for 15 min and read at 530 nm. Distilled water was used as a blank probe. TBA extract was obtained by combining 0.8 mL plasma and 0.4 mL TCA (trichloro acetic acid), then samples were put on ice for 10 minutes and centrifuged for 15 min at 6000 rpm. This method was described previously \[[@B54]\].

4.9. Determination of Antioxidant Enzymes {#sec4.9}
-----------------------------------------

Isolated RBCs were washed three times with 3 volumes of ice-cold 0.9 mmol/L NaCl, and hemolysates containing about 50 g Hb/L (prepared according to McCord and Fridovich \[[@B55]\]) were used for the determination of catalase (CAT) activity. CAT activity was determined according to Beutler \[[@B56]\]. Lysates were diluted with distilled water (1 : 7 v/v) and treated with chloroform-ethanol (0.6 : 1 v/v) to remove haemoglobin \[[@B57]\]. Then, 50 *μ*L catalase buffer, 100 *μ*L sample, and 1 mL 10 mM H~2~O~2~ were added to the samples. Detection was performed at 360 nm. Distilled water was used as a blank probe. Superoxide dismutase (SOD) activity was determined by the epinephrine method of Misra and Fridovich \[[@B58]\]. A hundred *μ*L lysate and 1 mL carbonate buffer were mixed, and then, 100 *μ*L of epinephrine was added. Detection was performed at 470 nm.

4.10. Statistics {#sec4.10}
----------------

The statistical analysis was performed with SPSS 10.0 for Windows. Results are expressed as the means ± standard deviation (median). Data on figures is presented as mean + standard deviation. After checking data distribution, the appropriate parametric or nonparametric test was used. The differences between two groups were assessed using *t*-test or Mann-Whitney test, while the differences between more than three groups were assessed using one-way ANOVA or Kruskal-Wallis test. For ANOVA posthoc analysis, Bonferroni test was used. To define the parameters that mostly change in ACSs, univariant logistic regression was used. Parameters that were marked as significant in univariant logistic regression entered multivariant logistic regression. Multivariant logistic regression marked parameters that were under independent effect of ACSs. *χ* ^2^ test was used to assess the difference in frequency of elevated levels of vWfAct and vWfAg. Based on the data about this frequency, sensitivity and specificity of the test (vWfAct and vWfAg test) were calculated. Based on the data about sensitivity and specificity of the test, the receiver operating characteristics (ROC) curve was determined.
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![Values of von Willebrand factor activity (%) in group of ACSs patient and in group of control subjects (mean + SD). Compared with control subjects, ACSs patients had statistically higher levels of vWfAct (175.27 ± 86.52 (166.0) % compared with 118.35 ± 33.11 (122.0) %; Mann-Whitney *U* test; \*\**P* \< 0.01).](OXIMED2011-918312.001){#fig1}

![Values of von Willebrand factor antigen (%) in group of ACSs patient and in group of control subjects (mean + SD). Compared with control subjects, ACSs patients had statistically higher levels of vWfAg (284.82 ± 126.66 (261.0) % compared with 104.57 ± 25.52 (108.0) %; *t*-test; \*\**P* \< 0.01).](OXIMED2011-918312.002){#fig2}

![Values of nitric oxide (nitrites) levels (nmol/mL) in group of ACSs patient and in group of control subjects (mean + SD). Compared with control subjects, ACSs patients had statistically lower levels of NO~2~ ^−^ (12.88 ± 8.40 (10.52) nmol/mL compared with 15.98 ± 6.05 (17.20) nmol/mL; Mann-Whitney *U* test; \**P* \< 0.05).](OXIMED2011-918312.003){#fig3}

![Values of superoxide anion radical levels (nmol/mL) in group of ACSs patient and in group of control subjects (mean + SD). ACSs patients and controls did not differ in levels of O~2~ ^−^ (9.34 + 7.83 (7.58) nmol/mL compared with 10.63 + 22.90 (5.27); Mann Whitney *U* test; *P* \> 0.05).](OXIMED2011-918312.004){#fig4}

![Values of hydrogen peroxide (nmol/mL) in group of ACSs patient and in group of control subjects (mean + SD). Compared with control subjects, ACSs patients had statistically lower levels of H~2~O~2~ (2.75 ± 2.56 (2.12) nmol/mL compared with 8.11 ± 7.52 (5.21); Mann Whitney *U* test; \*\**P* \< 0.01).](OXIMED2011-918312.005){#fig5}

![Values of index of lipid peroxidation (TBARS) levels (*μ*mol/mL) in group of ACSs patient and in group of control subjects (mean + SD). Compared with control subjects, ACSs patients had statistically higher TBARS compared with control subjects (3.12 ± 2.45 (2.48) U/g Hb × 10^3^ compared with 1.34 ± 0.47 (1.19) U/g Hb × 10^3^; *t*-test; \*\**P* \< 0.01).](OXIMED2011-918312.006){#fig6}

![Values of superoxide dismutase activity (U/g Hb × 10^3^) in group of ACSs patient and in group of control subjects (mean + SD). Compared with control subjects, ACSs patients had statistically lower SOD activity (156.83 ± 140.94 (89.54) U/g Hb × 10^3^ compared with 3078.21 ± 2664.35 (2433.71) U/g Hb × 10^3^; Mann-Whitney *U* test; \*\**P* \< 0.01).](OXIMED2011-918312.007){#fig7}

![Values of catalase activity (U/g Hb × 10^3^) in group of ACSs patient and in group of control subjects (mean + SD). Compared with control subjects, ACSs patients had statistically lower CAT activity (5.55 ± 4.99 (4.00) U/g Hb × 10^3^ compared with 7.80 ± 5.10 (6.87) U/g Hb × 10^3^; Mann-Whitney *U* test; \**P* \< 0.05).](OXIMED2011-918312.008){#fig8}

![Based on the data about sensitivity and specificity of the test (measuring vWfAct and vWfAg levels), receiver operating characteristic (ROC) curve as an indicator of the discriminating ability of the vWfAct and vWfAct test was obtained. ROC curve shows that the strength of vWfAg as an indicator of ACSs existence is very high.](OXIMED2011-918312.009){#fig9}

###### 

Demographic characteristics of investigated groups.

  Parameters                 ACSs patients   Controls
  -------------------------- --------------- ------------
  Number of patients (*n*)   115             40
  Sex (male/female)          74/41           26/14
  Age (*X* ± SD years)       67.0 ± 8.0      65.0 ± 3.0

###### 

Results of uni- and multivariant logistic regression related to the effects of ACSs existence to changes in examined biochemical parameters (exp*B*---relative risk; CI---confidence interval; \**P* \< 0.005; \*\**P* \< 0.001).

  Parameter   Univariant logistic regression   Multivariant logistic regression                          
  ----------- -------------------------------- ---------------------------------- ---------------------- -------------
  vWfAct      0.988 (0.981--0.994)             *P* = 0.000\*\*                    1.033 (0.984--1.084)   *P* = 0.193
  vWfAg       0.962 (0.947--0.976)             *P* = 0.000\*\*                    0.912 (0.810--1.027)   *P* = 0.130
  NO~2~ ^−^   1.062 (1.012--1,114)             *P* = 0.014\*\*                    1.010 (1.002--1.114)   *P* = 0.914
  O~2~ ^−^    1.005 (0.983--1.028)             *P* = 0.643                        ---                    ---
  H~2~O~2~    1.254 (1.124--1.400)             *P* = 0.000\*\*                    1.054 (1,024--1.300)   *P* = 0.988
  TBARS       0.399 (0.251--0.635)             *P* = 0.000\*\*                    0.999 (0.990--1.100)   *P* = 0.999
  SOD         1.007 (1.004--1.011)             *P* = 0.000\*\*                    1.017 (1.004--1.031)   *P* = 0.899
  CAT         1.046 (0.980--1.117)             *P* = 0.174                        ---                    ---

###### 

Frequencies of elevated levels of vWfAct and vWfAg in ACSs patients and controls.

                                    Group         Sig.       
  --------------- ----------------- ------------- ---------- -----------------
  vWfAg           Elevated levels   99 (86.1%)    0 (0.0%)   *P* = 0.000\*\*
  Normal levels   16 (13.9%)        40 (100.0%)              
  vWfAct          Elevated levels   62 (53.9%)    1 (2.5%)   *P* = 0.000\*\*
  Normal levels   53 (46.1%)        39 (97.5%)               

###### 

Levels of investigated biochemical parameters in different subgroups of subjects.

  --------------------------------------------------------------------------------------------
                        *X* ± SD (median)             Sig.
  --------------------- ----------------------------- ----------------------------------------
  vWfAct (%)                                          

                                                      

  STEMI (*n* = 65)      185.36 ± 95.25 (170.00)       Kruskal-Wallis test: *P* = 0.000\*\*\
                                                      *Mann-Whitney U test:*

  NSTEMI (*n* = 36)     167.92 ± 75.56 (168.50)       STEMI versus NSTEMI *P* = 0.173\
                                                      STEMI versus UA *P* = 0.072

  UA (*n* = 14)         130.48 ± 50.34 (121.00)       STEMI versus Control *P* = 0.000\*\*\
                                                      NSTEMI versus UA *P* = 0.214

  Control (*n* = 40)    118.35 ± 33.11 (122.00)       NSTEMI versus Control *P* = 0.001\*\*\
                                                      UA versus Control *P* = 0.819

                                                      

  vWfAg (%)                                           

                                                      

  STEMI                 317.21 ± 139.50 (302.00)      ONE way ANOVA: *P* = 0.000\*\*\
                                                      *Bonferroni:*

  NSTEMI                256.40 ± 95.23 (229.25)       STEMI versus NSTEMI *P* = 0.012\*\
                                                      STEMI versus UA *P* = 0.000\*\*

  UA                    169.27 ± 52.47 (181.50)       STEMI versus Control *P* = 0.000\*\*\
                                                      NSTEMI versus UA *P* = 0.021\*

  Control               104.57 ± 25.52 (108.00)       NSTEMI versus Control *P* = 0.000\*\*\
                                                      UA versus Control *P* = 0.991

                                                      

  O~2~ ^−^ (nmol/mL)                                  

                                                      

  STEMI                 8.90 ± 6.91 (7.25)            Kruskal-Wallis test: *P* = 0.284

  NSTEMI                9.68 ± 9.45 (7.58)            

  UA                    10.38 ± 0.57 (10.54)          

  Control               10.63 ± 22.90 (5.27)          

                                                      

  H~2~O~2~ (nmol/mL)                                  

                                                      

  STEMI                 2.70 ± 1.66 (2.14)            Kruskal-Wallis test: *P* = 0.000\*\*\
                                                      *Mann-Whitney U test:*

  NSTEMI                2.41 ± 2.04 (1.98)            STEMI versus NSTEMI *P* = 0.181\
                                                      STEMI versus UA *P* = 0.235

  UA                    5.06 ± 7.37 (1.66)            STEMI versus Control *P* = 0.000\*\*\
                                                      NSTEMI versus UA *P* = 0.872

  Control               8.11 ± 7.52 (5.21)            NSTEMI versus Control *P* = 0.000\*\*\
                                                      UA versus Control *P* = 0.000\*\*

                                                      

  NO~2~ ^−^ (nmol/mL)                                 

                                                      

  STEMI                 13.16 ± 7.57 (12.65)          ONE way ANOVA: *P* = 0.081

  NSTEMI                13.12 ± 9.62 (9.69)           

  UA                    9.54 ± 6.95 (7.22)            

  Control               15.98 ± 6.05 (17.20)          

                                                      

  TBARS (*μ*mol/mL)                                   

                                                      

  STEMI                 3.42 ± 2.61 (2.69)            Kruskal-Wallis test: *P* = 0.000\*\*\
                                                      *Mann-Whitney U test:*

  NSTEMI                2.96 ± 2.47 (2.21)            STEMI versus NSTEMI *P* = 0.999\
                                                      STEMI versus UA *P* = 0.999

  UA                    2.10 ± 0.56 (2.30)            STEMI versus Control *P* = 0.000\*\*\
                                                      NSTEMI versus UA *P* = 0.999

  Control               1.34 ± 0.47 (1.19)            NSTEMI versus Control *P* = 0.000\*\*\
                                                      UA versus Control *P* = 0.000\*\*

                                                      

  SOD (U/g Hb ×10^3^)                                 

                                                      

  STEMI                 185.04 ± 154.82 (124.54)      Kruskal-Wallis test: *P* = 0.000\*\*\
                                                      *Mann-Whitney U test:*

  NSTEMI                140.03 ± 129.84 (87.91)       STEMI versus NSTEMI *P* = 0.069\
                                                      STEMI versus UA *P* = 0.032\*

  UA                    67.20 ± 20.95 (66.34)         STEMI versus Control *P* = 0.000\*\*\
                                                      NSTEMI versus UA *P* = 0.615

  Control               3078.21 ± 2664.35 (2433.71)   NSTEMI versus Control *P* = 0.000\*\*\
                                                      UA versus Control *P* = 0.000\*\*

                                                      

  CAT (U/g Hb ×10^3^)                                 

                                                      

  STEMI                 5.94 ± 5.94 (3.25)            Kruskal-Wallis test: *P* = 0.159

  NSTEMI                5.30 ± 4.14 (4.37)            

  UA                    4.38 ± 2.65 (4.12)            

  Control               7.80 ± 5.10 (6.87)            
  --------------------------------------------------------------------------------------------

###### 

Results of uni- and multivariant logistic regression related to the effects of different type ACSs to changes in examined biochemical parameters (B---unstandardized regression coefficient; CI---confidence interval; \**P* \< 0.005; \*\**P* \< 0.001).

  Parameter   Univariate logistic regression   Multivariate logistic regression                               
  ----------- -------------------------------- ---------------------------------- --------------------------- -----------------
  vWfAct      −0.006 (−0.008--(−0.003))        *P* = 0.000\*\*                    0.000 (−0.004--0.003)       *P* = 0.948
  vWfAg       −0.006 (−0.007--(−0.005))        *P* = 0.000\*\*                    −0.004 (−0.006--(−0.001))   *P* = 0.007\*\*
  NO          0.027 (0.001--0.053)             *P* = 0.038\*                      −0.002 (−0.026--0.023)      *P* = 0.897
  O~2~        0.003 (−0.010--0.016)            *P* = 0.648                        ---                         ---
  H~2~O~2~    0.099 (0.064--0.133)             *P* = 0.000\*\*                    0.072 (0.013--0.131)        *P* = 0.018
  TBARS       −0.161 (−0.220--(−0.102))        *P* = 0.000\*\*                    −0.100 (−0.183--(−0.017))   *P* = 0.019\*
  SOD         0.000 (0.000--0.000)             *P* = 0.000\*\*                    0.001 (0.000--0.001)        *P* = 0.262
  CAT         0.015 (−0.024--0.053)            *P* = 0.450                        ---                         ---

###### 

Levels of investigated biochemical parameters in ACSs patients who survived and who deceased.

  Subjects                *X* ± SD (median)          Sig.
  ----------------------- -------------------------- ------------------------------------
  vWfAct (%)                                         
                                                     
  Survivors (*n* = 111)   172.00 ± 83.94 (168.00)    Mann-Whitney *U* test, *P* = 0.708
  Deceased (*n* = 4)      189.80 ± 105.94 (175.00)   
                                                     
  vWfAg (%)                                          
                                                     
  Survivors               274.86 ± 120.70 (241.00)   Mann-Whitney *U* test, *P* = 0.119
  Deceased                395.30 ± 182.16 (416.00)   
                                                     
  NO~2~ ^−^ (nmol/mL)                                
                                                     
  Survivors               12.68 ± 7.86 (12.32)       *t*-test, *P* = 0.998
  Deceased                12.67 ± 10.28 (8.18)       
                                                     
  O~2~ ^−^ (nmol/mL)                                 
                                                     
  Survivors               9.15 ± 10.68 (6.59)        Mann-Whitney *U* test, *P* = 0.150
  Deceased                15.42 ± 28.24 (3.62)       
                                                     
  H~2~O~2~ (nmol/mL)                                 
                                                     
  Survivors               2.99 ± 3.53 (2.20)         Mann-Whitney *U* test, *P* = 0.918
  Deceased                2.16 ± 0.56 (2.05)         
                                                     
  TBARS (*μ*mol/mL)                                  
                                                     
  Survivors               4.26 ± 3.39 (2.95)         Mann-Whitney *U* test, *P* = 0.394
  Deceased                5.24 ± 3.24 (5.06)         
                                                     
  SOD (U/g Hb × 10^3^)                               
                                                     
  Survivors               157.55 ± 125.22 (107.45)   Mann-Whitney *U* test, *P* = 0.836
  Deceased                175.82 ± 198,86 (118.03)   
                                                     
  CAT (U/g Hb × 10^3^)                               
                                                     
  Survivors               6.16 ± 5.22 (4.00)         Mann-Whitney *U* test, *P* = 0.073
  Deceased                11.30 ± 7.36 (10.00)       

###### 

Univariant logistic regression regarding effects of biochemical parameters on outcome of ACSs patients (exp*B*---relative risk; CI---confidence interval).

  Parameter   Univariant logistic regression   
  ----------- -------------------------------- -------------
  vWfAct      1.002 (0.992--1.013)             *P* = 0.647
  vWfAg       1.006 (1.000--1.013)             *P* = 0.052
  NO~2~ ^−^   1.000 (0.892--1.121)             *P* = 0.998
  O~2~        1.026 (0.979--1.075)             *P* = 0.291
  H~2~O~2~    0.846 (0.447--1.599)             *P* = 0.606
  TBARS       1.083 (0.843--1.391)             *P* = 0.531
  SOD         1.001 (1.995--1.008)             *P* = 0.757
  CAT         1.120 (0.995--1.262)             *P* = 0.061

[^1]: Academic Editor: Kenneth Maiese
